Moderna/Merck begins late-stage study of skin cancer vaccine combination

Moderna said on Wednesday it has begun enrolling patients in a late-stage study evaluating its personalised mRNA-based skin cancer vaccine in combination with drugmaker Merck's blockbuster therapy Keytruda.